MTOR and renal cell carcinoma: These same effects were observed in ACHN cells that express wild-type p53, demonstrating that C-DIM/NR4A1 antagonists represent a novel class of mTOR inhibitors with clinical potential for treating RCC patients expressing NR4A1 and wild-type p53 (Fig 6).